Non-Cochrane · prognostic · PM42018484
Salivary and lacrimal disorders in patients treated with radioiodine for differentiated thyroid cancer.
Bondet de La Bernardie Soline, Bernier Marie-Odile, Buffet Camille, et al. · European thyroid journal · 2026 · PubMed · doi:10.1530/etj-25-0402
Findings
Population Patients with differentiated thyroid cancer treated with radioiodine (I131)
9 findings
| Radioiodine (I131) therapy | None | Xerostomia (pooled prevalence) more than 1 year after RIT | Prevalence 0.17 [0.10, 0.28] GRADE not reported 6 studies · 1005 participants |
| Radioiodine (I131) therapy | None | Sialadenitis (pooled prevalence) between 6 months and 1 year after RIT | Prevalence 0.20 [0.12, 0.31] GRADE not reported 3 studies · 527 participants |
| Radioiodine (I131) therapy | None | Sialadenitis (pooled prevalence) more than 1 year after RIT | Prevalence 0.24 [0.21, 0.29] GRADE not reported 3 studies · 405 participants |
| Radioiodine (I131) therapy | None | Xerostomia (pooled prevalence) between 2 and 6 months after RIT | Prevalence 0.37 [0.28, 0.47] GRADE not reported 4 studies · 392 participants |
| Radioiodine (I131) therapy | None | Sialadenitis (pooled prevalence) within 2 months after RIT | Prevalence 0.30 [0.12, 0.59] GRADE not reported 3 studies · 1563 participants |
| Radioiodine (I131) therapy | None | Xerostomia (pooled prevalence) between 6 months and 1 year after RIT | Prevalence 0.19 [0.14, 0.25] GRADE not reported 5 studies · 885 participants |
| Radioiodine (I131) therapy | None | Xerostomia (pooled prevalence) within 2 months after RIT | Prevalence 0.60 [0.28, 0.85] GRADE not reported 3 studies · 1502 participants |
| High administered I131 activity (study-specific thresholds) | Low administered I131 activity (study-specific thresholds) | Xerostomia Sensitivity analysis excluding Solans et al. | OR 7.14 [2.02, 25.26] GRADE not reported 3 studies |
| High administered I131 activity (study-specific thresholds) | Low administered I131 activity (study-specific thresholds) | Xerostomia Overall (random effects) | OR 4.23 [1.04, 17.15] GRADE not reported 4 studies |
Included primary studies 73
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Chow 2021 Association between quality of life and patient-reported complications from surgery and radioiodine in early-stage thyroid cancer… PMID:33648765 | 2021 | 1 other review | Xerostomia (pooled prevalence) | not extracted yet |
| Albano 2017 Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer DOI:10.1002/pbc.26595 | 2017 | this review only | not stated | not extracted yet |
| Albano 2017 Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer. PMID:28436606 | 2017 | this review only | not stated | not extracted yet |
| Almeida 2009 Clinical Predictors of Quality of Life in Patients With Initial Differentiated Thyroid Cancers DOI:10.1001/archoto.2009.16 | 2009 | this review only | not stated | not extracted yet |
| Almeida 2009 Clinical predictors of quality of life in patients with initial differentiated thyroid cancers. PMID:19380354 | 2009 | this review only | not stated | not extracted yet |
| Almeida 2011 Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer DOI:10.1002/hed.21520 | 2010 | this review only | not stated | not extracted yet |
| Almeida 2011 Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. PMID:21484917 | 2011 | this review only | not stated | not extracted yet |
| Badam 2016 Assessment of Salivary Gland Function Using Salivary Scintigraphy in Pre and Post Radioactive Iodine Therapy in Diagnosed Thyroid… PMID:26894178 | 2016 | this review only | not stated | not extracted yet |
| Baudin 2023 Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of… DOI:10.1089/thy.2023.0090 | 2023 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Baudin 2023 Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of… PMID:37300484 | 2023 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Bulut 2018 Impact of sialendoscopy on improving health related quality of life in patients suffering from radioiodineinduced xerostomia DOI:10.3413/nukmed-0964-18-03 | 2018 | this review only | not stated | not extracted yet |
| Bulut 2018 Impact of sialendoscopy on improving health related quality of life in patients suffering from radioiodineinduced xerostomia. PMID:30125928 | 2018 | this review only | not stated | not extracted yet |
| Caglar 2002 Scintigraphic Evaluation of Salivary Gland Dysfunction in Patients with Thyroid Cancer After Radioiodine Treatment DOI:10.1097/00003072-200211000-00003 | 2002 | this review only | Xerostomia | not extracted yet |
| Caglar 2002 Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. PMID:12394122 | 2002 | this review only | Xerostomia | not extracted yet |
| Chow 2021 Association between quality of life and patient-reported complications from surgery and radioiodine in early-stage thyroid cancer… DOI:10.1016/j.surg.2021.01.022 | 2021 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| da Fonseca 2017 Correlation among ocular surface disease, xerostomia, and nasal symptoms in patients with differentiated thyroid carcinoma subjected to… PMID:28945293 | 2017 | this review only | not stated | not extracted yet |
| Daniel 2018 Salivary evaluation in radioactive I<sup>131</sup> treated patients with thyroid carcinoma DOI:10.1080/00016357.2017.1399214 | 2017 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Daniel 2018 Salivary evaluation in radioactive I131 treated patients with thyroid carcinoma. PMID:29125000 | 2018 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Dingle 2013 Salivary Morbidity and Quality of Life following Radioactive Iodine for Well‐Differentiated Thyroid Cancer DOI:10.1177/0194599813479777 | 2013 | this review only | not stated | not extracted yet |
| Dingle 2013 Salivary morbidity and quality of life following radioactive iodine for well-differentiated thyroid cancer. PMID:23462656 | 2013 | this review only | not stated | not extracted yet |
| Eiras Ramim 2020 Health-related quality of life of thyroid cancer patients undergoing radioiodine therapy: a cohort real-world study in a reference public… DOI:10.1007/s00520-019-05225-x | 2019 | this review only | not stated | not extracted yet |
| Eiras Ramim 2020 Health-related quality of life of thyroid cancer patients undergoing radioiodine therapy: a cohort real-world study in a reference public… PMID:31832820 | 2020 | this review only | not stated | not extracted yet |
| Florenzano 2016 Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer DOI:10.1155/2016/2586512 | 2016 | this review only | not stated | not extracted yet |
| Florenzano 2016 Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer. PMID:27867395 | 2016 | this review only | not stated | not extracted yet |
| Geres 2015 Sialoadenitis por radioyodo. Análisis de factores que influyen en la respuesta al tratamiento médico DOI:10.1016/j.endonu.2015.07.006 | 2015 | this review only | not stated | not extracted yet |
| Geres 2015 Sialadenitis after radioiodine therapy. Analysis of factors that influence the response to medical treatment. PMID:26459118 | 2015 | this review only | not stated | not extracted yet |
| Goswami 2019 Clinical factors associated with worse quality-of-life scores in United States thyroid cancer survivors DOI:10.1016/j.surg.2019.01.034 | 2019 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Goswami 2019 Clinical factors associated with worse quality-of-life scores in United States thyroid cancer survivors. PMID:30898373 | 2019 | this review only | Xerostomia (pooled prevalence); Sialadenitis (pooled prevalence) | not extracted yet |
| Grewal 2009 Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation DOI:10.2967/jnumed.108.061382 | 2009 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Grewal 2009 Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. PMID:19759114 | 2009 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Hedman 2017 Effect of Thyroid-Related Symptoms on Long-Term Quality of Life in Patients with Differentiated Thyroid Carcinoma: A Population-Based… DOI:10.1089/thy.2016.0604 | 2017 | this review only | not stated | not extracted yet |
| Hedman 2017 Effect of Thyroid-Related Symptoms on Long-Term Quality of Life in Patients with Differentiated Thyroid Carcinoma: A Population-Based… PMID:28474541 | 2017 | this review only | not stated | not extracted yet |
| Hollingsworth 2016 Risk Factors of <sup>131</sup>I-Induced Salivary Gland Damage in Thyroid Cancer Patients DOI:10.1210/jc.2016-1605 | 2016 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Hollingsworth 2016 Risk Factors of 131I-Induced Salivary Gland Damage in Thyroid Cancer Patients. PMID:27533304 | 2016 | this review only | Sialadenitis (pooled prevalence) | not extracted yet |
| Horvath 2020 Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine… DOI:10.1089/thy.2019.0563 | 2020 | this review only | not stated | not extracted yet |
| Horvath 2020 Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine… PMID:32370663 | 2020 | this review only | not stated | not extracted yet |
| Huang 2021 Progressive changes in the major salivary gland after radioiodine therapy for differentiated thyroid cancer: a single-center retrospective… DOI:10.1016/j.ultrasmedbio.2021.05.013 | 2021 | this review only | not stated | not extracted yet |
| Huang 2021 Progressive changes in the major salivary gland after radioiodine therapy for differentiated thyroid cancer: a single-center retrospective… PMID:34147311 | 2021 | this review only | not stated | not extracted yet |
| Hyer 2007 Salivary Gland Toxicity after Radioiodine Therapy for Thyroid Cancer DOI:10.1016/j.clon.2006.11.005 | 2007 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Hyer 2007 Salivary gland toxicity after radioiodine therapy for thyroid cancer. PMID:17305259 | 2007 | this review only | Xerostomia (pooled prevalence); Sialadenitis (pooled prevalence) | not extracted yet |
| Iakovou 2015 Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine… PMID:25537365 | 2016 | this review only | Xerostomia (pooled prevalence); Sialadenitis (pooled prevalence) | not extracted yet |
| Iakovou 2016 Effect of recombinant human thyroid‐stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine… DOI:10.1002/hed.23974 | 2015 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Jeong 2013 Salivary Gland Function 5 Years After Radioactive Iodine Ablation in Patients with Differentiated Thyroid Cancer: Direct Comparison of… DOI:10.1089/thy.2012.0106 | 2013 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Jeong 2013 Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of… PMID:23153322 | 2013 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Klein Hesselink 2016 Effects of Radioiodine Treatment on Salivary Gland Function in Patients with Differentiated Thyroid Carcinoma: A Prospective Study DOI:10.2967/jnumed.115.169888 | 2016 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Klein Hesselink 2016 Effects of Radioiodine Treatment on Salivary Gland Function in Patients with Differentiated Thyroid Carcinoma: A Prospective Study. PMID:27339871 | 2016 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Krcalova 2020 Scintigraphic evaluation of salivary gland function in thyroid cancer patients after radioiodine remnant ablation DOI:10.1111/eos.12689 | 2020 | this review only | not stated | not extracted yet |
| Krcalova 2020 Scintigraphic evaluation of salivary gland function in thyroid cancer patients after radioiodine remnant ablation. PMID:32239618 | 2020 | this review only | not stated | not extracted yet |
| Le Roux 2020 Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: Long‐term study DOI:10.1002/hed.26359 | 2020 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Le Roux 2020 Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: Long-term study. PMID:32652742 | 2020 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Lee 2015 Salivary gland dysfunction after radioactive iodine (I-131) therapy in patients following total thyroidectomy: emphasis on radioactive… DOI:10.1016/j.clinimag.2014.12.018 | 2015 | this review only | not stated | not extracted yet |
| Lee 2015 Salivary gland dysfunction after radioactive iodine (I-131) therapy in patients following total thyroidectomy: emphasis on radioactive… PMID:25630229 | 2015 | this review only | not stated | not extracted yet |
| Lopes da Fonseca 2017 Correlation among ocular surface disease, xerostomia, and nasal symptoms in patients with differentiated thyroid carcinoma subjected to… DOI:10.1002/hed.24895 | 2017 | this review only | not stated | not extracted yet |
| Makarenko 2024 matched by author and year (probable) | NR | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Makarenko 2024 Thromboxane receptor stimulation inhibits adenylate cyclase and reduces cyclic AMP-mediated inhibition of ADP-evoked responses in… PMID:1312024 | 1992 | this review only | Xerostomia (pooled prevalence); Sialadenitis (pooled prevalence) | not extracted yet |
| Maruoka 2017 A Functional Scoring System Based on Salivary Gland Scintigraphy for Evaluating Salivary Gland Dysfunction Secondary to 131I therapy in… PMID:28969240 | 2017 | this review only | Xerostomia (pooled prevalence); Xerostomia | not extracted yet |
| Ming 2022 Effect of radioiodine therapy under thyroid hormone withdrawal on health-related quality of life in patients with differentiated thyroid… DOI:10.1093/jjco/hyac113 | 2022 | this review only | not stated | not extracted yet |
| Ming 2022 Effect of radioiodine therapy under thyroid hormone withdrawal on health-related quality of life in patients with differentiated thyroid… PMID:35848939 | 2022 | this review only | not stated | not extracted yet |
| Missaoui 2022 Health-related quality of life in long-term differentiated thyroid cancer survivors: A cross-sectional Tunisian-based study DOI:10.3389/fendo.2022.999331 | 2022 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Missaoui 2022 Health-related quality of life in long-term differentiated thyroid cancer survivors: A cross-sectional Tunisian-based study. PMID:36093070 | 2022 | this review only | Sialadenitis (pooled prevalence) | not extracted yet |
| Nabaa 2012 Assessment of Salivary Gland Dysfunction after Radioiodine Therapy for Thyroid Carcinoma Using Non-Contrast-Enhanced CT: The Significance… DOI:10.3174/ajnr.a3063 | 2012 | this review only | not stated | not extracted yet |
| Nabaa 2012 Assessment of salivary gland dysfunction after radioiodine therapy for thyroid carcinoma using non-contrast-enhanced CT: the significance… PMID:22555571 | 2012 | this review only | not stated | not extracted yet |
| Rogers 2017 Health-related quality of life, fear of recurrence, and emotional distress in patients treated for thyroid cancer DOI:10.1016/j.bjoms.2016.09.001 | 2017 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Rogers 2017 Health-related quality of life, fear of recurrence, and emotional distress in patients treated for thyroid cancer. PMID:28648407 | 2017 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Selvakumar 2019 Long-Term Effects of Radioiodine Treatment on Salivary Gland Function in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma DOI:10.2967/jnumed.118.212449 | 2018 | this review only | not stated | not extracted yet |
| Selvakumar 2019 Long-term effects of radioiodine treatment on salivary gland function in adult survivors of pediatric differentiated thyroid carcinoma. PMID:30504138 | 2018 | this review only | not stated | not extracted yet |
| Solans 2001 Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. PMID:11337569 | 2001 | this review only | Xerostomia (pooled prevalence); Xerostomia | not extracted yet |
| Tabari 2024 Subjective and objective effects of radioiodine therapy on the sense of smell DOI:10.1007/s00405-024-08761-3 | 2024 | this review only | not stated | not extracted yet |
| Tabari 2024 Subjective and objective effects of radioiodine therapy on the sense of smell. PMID:39127798 | 2024 | this review only | not stated | not extracted yet |
| Walter 2007 The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study DOI:10.2967/jnumed.107.042192 | 2007 | this review only | Xerostomia (pooled prevalence) | not extracted yet |
| Walter 2007 The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. PMID:17873131 | 2007 | this review only | Sialadenitis (pooled prevalence) | not extracted yet |
| Wu 2015 Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative… DOI:10.1097/mnm.0000000000000325 | 2015 | this review only | Xerostomia (pooled prevalence); Xerostomia | not extracted yet |
| Wu Feng 2015 Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative… PMID:25932534 | 2015 | this review only | Xerostomia (pooled prevalence); Xerostomia | not extracted yet |
Overlap with other reviews
Reviews that include the same primary studies are not independent evidence. Shared counts match studies by PMID, DOI or NCT, and otherwise by author and year (a probable match). Only the non-Cochrane dental reviews have study lists, so overlap with Cochrane reviews is not counted yet.
| Review | Shared studies | Jaccard |
|---|---|---|
| Reassessing Radioactive Iodine Use After Thyroidectomy in Low-Risk Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis. (2026) | 1 | 0.01 |
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Thyroid cancer patients treated with I131 | Patients with differentiated thyroid cancer treated with RIT (38 studies; 16 in meta-analyses) |
| Intervention | Radioiodine (I131) therapy | Radioiodine (I131) therapy; high vs low administered activity |
| Comparison | Not specified | Low administered I131 activity (study-specific thresholds) for the OR analysis |
| Outcomes | Salivary and lacrimal dysfunction (xerostomia, sialadenitis, xerophthalmia) | Xerostomia prevalence (<2 months, 2-6 months, 6-12 months, >1 year); sialadenitis prevalence (<2 months, 6-12 months, >1 year); xerostomia OR high vs low activity (4 studies) |
| Study designs | Observational studies (cohort, longitudinal, case-control, cross-sectional), English, 2000 to 2024 | 26 cohort and 9 cross-sectional studies among 38 included |
| Timing | Not specified | Within 2 months; 2-6 months; 6-12 months; more than 1 year |